Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: (908) 967-6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

donein12 Oct. 24 at 6:20 PM

$CTOR The Q&A the other day, it was said they are planning to launch LYMPHIR by the end of the month . So that means by next Friday. Any other stock would be way up on that. Just shows the lack of confidence and trust investors has in CTOR/CTXR management.

1 · Reply

mawadaty Oct. 24 at 5:16 PM

$CTOR unbeleviable herd of sheep as they will need to have a herder from WS to lead them to buy or sell ... if WS deep pocket is buying now the retail will be like a flies on a turd .. this a great product and solid company better than shell companies you are chasing and buying $100-200 for the share just becuase a crook of WS was buying it . Clueless crowd

0 · Reply

mawadaty Oct. 24 at 4:00 PM

$CTOR FKN shorts need a taste of cancer so they can appriciate any meds that will help them survive. There whole premise here that this approved med by CTOR is a third choice by doctors. They need to go interview doctors and patience in any onclogy hospital as them if they pick and choose between meds to give ton the patient and patient will tell just give any med that will help survive.

0 · Reply

mawadaty Oct. 24 at 3:56 PM

$CTOR Hell People at least this company managed to get an approval for a cancer treatment product, most pharma research companies struggle to go through phase 1 much less get approval especially in the Oncology arena. This should be $50+ regardless as they will sell the crap out of that cancer product whether it is first or third or even tenth choice by doctors. Have you seen the cancer patient in hospital, they have no choice either die or take the toxic medicine and pray and hope that it works. My son had Neuroblastoma as a child and there were no products out there to help him. The doctor told me there was a med on trial and that the only and last choice for my son, I signed up to give him that unapproved medicine and he survived.

0 · Reply

NYC100 Oct. 23 at 9:29 PM

$CTOR you sound very desperate 😂😂

1 · Reply

Jojackthewonderskunk Oct. 23 at 9:29 PM

$CTOR Nuh-

0 · Reply

TwongStocks Oct. 23 at 9:13 PM

$CTOR Updated investor slides https://s204.q4cdn.com/372710200/files/doc_presentations/2025/Oct/23/Citius-Oncology-Overview-OCT-2025-FINAL.pdf

0 · Reply

SweStonk Oct. 23 at 4:04 PM

$CTOR zoom out and we see lower lows.

0 · Reply

TwongStocks Oct. 23 at 3:48 PM

$CTOR $CTXR My favorite is when two people get in an an argument, but instead of keeping that argument in a single thread, they just continually quote each other.

2 · Reply

SweStonk Oct. 23 at 3:44 PM

$CTOR $CTXR Still 0 counter arguments to why anyone would be bullish. Atleast I give arguments to why Im bearish. You invest here for what? Third in line treatment that will bring 10m/y. They be lucky to get a couple patients on an already small patient population.

1 · Reply

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 17, 2025, 5:00 PM EDT - 8 days ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

Oct 16, 2025, 8:47 AM EDT - 9 days ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTXR

Oct 7, 2025, 8:47 AM EDT - 18 days ago

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Sep 10, 2025, 4:30 PM EDT - 6 weeks ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Sep 9, 2025, 8:30 AM EDT - 6 weeks ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Aug 22, 2025, 8:47 AM EDT - 2 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTXR

Aug 12, 2025, 4:30 PM EDT - 2 months ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Jul 17, 2025, 4:30 PM EDT - 3 months ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTXR

Jul 16, 2025, 9:15 AM EDT - 3 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTXR

Jul 15, 2025, 8:32 AM EDT - 3 months ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTXR

Jun 17, 2025, 8:08 AM EDT - 4 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTXR

May 14, 2025, 4:30 PM EDT - 5 months ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:37 AM EDT - 6 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTXR

Feb 14, 2025, 4:30 PM EST - 9 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTXR

Feb 14, 2025, 4:30 PM EST - 9 months ago

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 6, 2025, 8:55 AM EST - 9 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

Jan 7, 2025, 8:08 AM EST - 10 months ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

Jan 6, 2025, 7:50 AM EST - 10 months ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

Dec 27, 2024, 5:00 PM EST - 10 months ago

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

donein12 Oct. 24 at 6:20 PM

1 · Reply

mawadaty Oct. 24 at 5:16 PM

0 · Reply

mawadaty Oct. 24 at 4:00 PM

0 · Reply

mawadaty Oct. 24 at 3:56 PM

0 · Reply

NYC100 Oct. 23 at 9:29 PM

$CTOR you sound very desperate 😂😂

1 · Reply

Jojackthewonderskunk Oct. 23 at 9:29 PM

$CTOR Nuh-

0 · Reply

TwongStocks Oct. 23 at 9:13 PM

$CTOR Updated investor slides https://s204.q4cdn.com/372710200/files/doc_presentations/2025/Oct/23/Citius-Oncology-Overview-OCT-2025-FINAL.pdf

0 · Reply

SweStonk Oct. 23 at 4:04 PM

$CTOR zoom out and we see lower lows.

0 · Reply

TwongStocks Oct. 23 at 3:48 PM

$CTOR $CTXR My favorite is when two people get in an an argument, but instead of keeping that argument in a single thread, they just continually quote each other.

2 · Reply

SweStonk Oct. 23 at 3:44 PM

1 · Reply

BALUGA825 Oct. 23 at 2:49 PM

$CTOR $CTXR So str8 up bashing this stock to get a discount. GOT IT!

1 · Reply

BALUGA825 Oct. 22 at 9:47 PM

$CTOR $CTXR LoL Why would they beleive you held and sold ? Contradicting your post all the time. Your full of shit!

1 · Reply

SweStonk Oct. 22 at 8:03 PM

$CTOR $CTXR You should read before comment. You should re read before sharing. I have no position here. Sold @ ~$2.1 on CTXR and ~$2.66 on CTOR. Mazur will never give up CTOR. If he distribute he wont have full control. When he choose to sell ML and not the company it is clear as day. Why do you think the SP have dropped this much after the conference? Why Mazur didnt hold the conference? Some people really want nothing more than to blow their portfolio..... SAVA all over this.

0 · Reply

NYC100 Oct. 22 at 6:56 PM

$CTOR $CTXR I think you should sell it if you’re so afraid

1 · Reply

SweStonk Oct. 22 at 5:54 PM

$CTOR $CTXR He about to fuck every investor in CTXR. Selling the main asset and not the company(CTXR) and already spun off the other asset(lymphir) is very bad news. CTXR will be worthless and only a holding company while management benefit from getting free shares in CTOR. There are only a handful of companies that have done this before and they all went bankrupt. This is very bad news. When trust is gone so is the company. What makes you think it will be different in CTOR? After investors know what he have done why would anyone trust him with their own money? I have waited for an opportunity to enter cheaper because of ML but this is very very slimy of him. Their estimates are completely off for Lymphir and it seems they are trying to blow up the value. Competition with more patients and better efficiancy dont have revenue anywhere near their estimates. Never thought in my life that applebot was about to be correct about all of this.

0 · Reply

donein12 Oct. 22 at 4:06 PM

$CTOR One would think CTOR would be strong today During the Q&A, he stated that they were planning to launch LYMPHIR by the end of the month = But it is down 6%. SMH. Yesterday it was stated: LYMPHIR • During the Q&A, he stated that they were planning to launch LYMPHIR by the end of the month • In process of signing additional international agreements for LYMPHIR, plan to cover 38 countries by EoY. Price of drug in US is expected to be $326,000 per patient per year • Expect year initial sales to be under $100M in first 12 months, profitable within first 9 months. Year 4 sales expected to be $400M • Trial combining LYMPHIR with KEYTRUDA: seeing 40% ORR in in-stage GYN cancers & they are in mature discusssions with Merck • Trial combining LYMPHIR with CAR-T: seeing 91% resposne rates in refractory B-cell lymphomas • CTOR has 18 months of LYMPHIR in inventory. CTOR raised $9M last month, will be doing another raise in the next few weeks to support the commercial launch

0 · Reply

BALUGA825 Oct. 21 at 11:22 PM

$CTOR $CTXR Let me get this str8: FDA approved drug will be launch this month and the other d4ug on phase 3 trial will get a green light this year. Did i read that right ?

0 · Reply

TwongStocks Oct. 21 at 8:51 PM

$CTXR SEC filing confirms a 90 day lockup. One exception is that they can use the ATM after 30 days, but only above $2.15 https://www.sec.gov/ix?doc=/Archives/edgar/data/1506251/000121390025100847/ea0261909-8k_citius.htm "Pursuant to the Purchase Agreement, the Company agreed for a period of 90 days following the closing of the Offering not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of the shares or any other securities convertible into, or exercisable or exchangeable for, shares of common stock, subject to certain exceptions; provided that after 30 days after closing, the Company may issue shares of common stock in an “at the market” offering with the placement agent as sales agent at an offering price equal to or greater than $2.15 per share." Earliest $CTOR can raise again is Nov 14, when the lockup from their Sept offering expires. Earliest CTXR can raise again is Jan 19, 2026, ninety days from today.

1 · Reply

TwongStocks Oct. 21 at 7:00 PM

$CTXR $CTOR Recap of today's presentation. Interestingly, Leonard did not give the presentation. This was Paul Sowyrda, VP of Business Development & Market Intelligence. LYMPHIR • During the Q&A, he stated that they were planning to launch LYMPHIR by the end of the month • In process of signing additional international agreements for LYMPHIR, plan to cover 38 countries by EoY. Price of drug in US is expected to be $326,000 per patient per year • Expect year initial sales to be under $100M in first 12 months, profitable within first 9 months. Year 4 sales expected to be $400M • Trial combining LYMPHIR with KEYTRUDA: seeing 40% ORR in in-stage GYN cancers & they are in mature discusssions with Merck • Trial combining LYMPHIR with CAR-T: seeing 91% resposne rates in refractory B-cell lymphomas • CTOR has 18 months of LYMPHIR in inventory. CTOR raised $9M last month, will be doing another raise in the next few weeks to support the commercial launch More in comments

4 · Reply

PoeDallas Oct. 21 at 6:07 PM

$CTXR Launch the drug this month?! Expectation 100m within first 12 months and profitable year 1. -Plans to sell off HL/ ML and CTXR will be dissolved to continue with CTOR -Next month expect HL trial 3 from FDA details. -another $CTOR raise in a few weeks. -Before end of year more info about CTXR/ CTOR share distribution This is big news.

1 · Reply

Bronco6970 Oct. 21 at 4:23 PM

$CTOR twongstocks AKA “Leonard Mazur” still here supporting this pile of poo. While Leonard dilutes you all to death to pay for his beautiful mansion on the Lake. 💩

1 · Reply

TwongStocks Oct. 21 at 3:47 PM

$CTXR is presenting today at the LD Micro Main Event. While this is technically for CTXR, today's presentation will likely also cover $CTOR and LYMPHIR. CTXR is scheduled to present Oct 21 at 10:30am -11:00am PT (1:30pm - 2:00pm ET). This conference is in San Diego, so the listed times are for the Pacific time zone. Registration link for the webcast ---> https://ldmicrocasts.com/ After you register, select Track 4 to view the CTXR presentation. CTXR will present on Track 4 after TOMZ.

0 · Reply

Market Cap	143.64M
Revenue (ttm)	0.00
Net Income (ttm)	-21.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.35

Volume	166,800
Avg Vol	244,932
Day's Range	N/A - N/A
Shares Out	83.51M
Stochastic %K	21%
Beta	2.92
Analysts	Strong Sell
Price Target	$6.00